Stocks and Investing
Stocks and Investing
Fri, May 28, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, May 27, 2021
David Lebowitz Initiated (ARQT) at Buy and Held Target at $52 on, May 27th, 2021
David Lebowitz of Morgan Stanley, Initiated "Arcutis Biotherapeutics, Inc." (ARQT) at Buy and Held Target at $52 on, May 27th, 2021.
David has made no other calls on ARQT in the last 4 months.
There are 2 other peers that have a rating on ARQT. Out of the 2 peers that are also analyzing ARQT, 0 agree with David's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with David
- Gregg Gilbert of "Truist Securities" Maintained at Strong Buy with Increased Target to $48 on, Tuesday, February 2nd, 2021
- Ken Cacciatore of "Cowen & Co." Maintained at Buy with Increased Target to $80 on, Monday, February 1st, 2021
Contributing Sources